Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Medical Universtity of Lodz |
---|---|
Information provided by: | Medical Universtity of Lodz |
ClinicalTrials.gov Identifier: | NCT00500253 |
The aim of this study is to assess the utility of exhaled nitric oxide measurement (FeNO) in treatment monitoring in children with asthma.
According to the aim of the study following assumptions are formulated:
Condition | Intervention | Phase |
---|---|---|
Asthma |
Device: exhaled nitric oxide measurement Procedure: bronchial hyperresponsiveness with methacholine (PC20M) Procedure: symptom score diary (according to 2007 GINA guidelines) |
Phase IV |
Study Type: | Observational |
Study Design: | Screening, Longitudinal, Defined Population, Prospective Study |
Official Title: | Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma |
Estimated Enrollment: | 120 |
Study Start Date: | February 2007 |
Estimated Study Completion Date: | December 2008 |
Asthma is one of the most common chronic disease worldwide, imposing a substantial social burden on both children and adults.
What needs to be kept in mind, especially in assessing treatment effect of allergic inflammation in children with asthma, is that symptom score and spirometry measures have limitations, mainly their subjectivity (symptom scores), wide variability, and lack of stability in short time period (symptom scores and spirometry measures).
Monitoring allergic inflammation in the course of asthma in children with exhaled nitric oxide measurement (FeNO) may allow to titrate the dose of inhaled glucocorticosteroids more precisely, depending on individual patients requirements.
The aim of this study is to assess the utility of FeNO in treatment monitoring in children with asthma.
According to the aim of the study following assumptions are formulated:
Ages Eligible for Study: | 6 Years to 18 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Anna Sołoniewicz, MD | 00 48 42 6895972 | alergol@kopernik.lodz.pl |
Poland | |
Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland | Recruiting |
Lodz, Poland, 93-513 | |
Contact: Anna Sołoniewicz, MD 00 48 42 6895972 alergol@kopernik.lodz.pl | |
Sub-Investigator: Anna Sołoniewicz, MD | |
Principal Investigator: Iwona Stelmach, MD, PhD, Prof |
Principal Investigator: | Anna Sołoniewicz, MD | Department of Pediatrics and Allergy, Medical University of Lodz, Poland |
Study Chair: | Iwona Stelmach, MD, PhD, Prof | Department of Pediatrics and Allergy, Medical University of Lodz, Poland |
Study ID Numbers: | RNN-56-07-KE |
Study First Received: | July 11, 2007 |
Last Updated: | July 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00500253 |
Health Authority: | Poland: Ministry of Health |
exhaled nitric oxide asthma children inhaled glucocorticosteroids |
Nitric Oxide Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Methacholine Chloride Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity |
Parasympathomimetics Respiratory System Agents Vasodilator Agents Neurotransmitter Agents Antioxidants Cholinergic Agonists Bronchial Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Bronchoconstrictor Agents Miotics Physiological Effects of Drugs |
Anti-Asthmatic Agents Cardiovascular Agents Cholinergic Agents Protective Agents Pharmacologic Actions Autonomic Agents Therapeutic Uses Free Radical Scavengers Muscarinic Agonists Endothelium-Dependent Relaxing Factors Peripheral Nervous System Agents Bronchodilator Agents |